Category

Immune System Diseases 

Immune Responses Regulated by Cannabidiol.

By | Immune System Diseases , Inflammation

Authors: James M. Nichols and Barbara L.F. Kaplan
Cannabis and Cannabinoid Research, 4 September 2019

Introduction: Cannabidiol (CBD) as Epidiolex® (GW Pharmaceuticals) was recently approved by the U.S. Food and Drug Administration (FDA) to treat rare forms of epilepsy in patients 2 years of age and older. Together with the increased societal acceptance of recreational cannabi…

Read More

The influence of THC:CBD oromucosal spray on driving ability in patients with multiple sclerosis-related spasticity.

By | Driving, Immune System Diseases , Multiple Sclerosis, Muscle Spasticity, Muscular Diseases

Authors: Elisabeth G. Celius, Carlos Vila
Brain and Behavior, 6 April 2018

BACKGROUND: Driving ability is a key function for the majority of patients with multiple sclerosis (MS) to help maintain daily interactions. Both physical and cognitive disability, as well as treatments, may affect the ability to drive. Spasticity is a common symptom associate…

Read More

Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation.

By | Immune System Diseases , Multiple Sclerosis

Authors: Atheer Zgair, Jong Bong Lee, Jonathan C. M. Wong, Dhiaa A. Taha, Jehan Aram, et al
Scientific Reports, 6 November 2017

Cannabidiol (CBD) and ∆9-tetrahydrocannabinol (THC) have well documented immunomodulatory effects in vitro, but not following oral administration in humans. Here we show that oral co-administration of cannabinoids with lipids can substantially increase their intestinal lympha…

Read More

Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis.

By | Immune System Diseases , Multiple Sclerosis

Authors: R. B. C. Kavia, D. De Ridder, C. S. Constantinescu, C. G. Stott, C. J. Fowler
Multiple Sclerosis Journal, November 2016

BACKGROUND: Bladder dysfunction is a common feature of multiple sclerosis (MS). OBJECTIVE: In this study we aimed to assess the efficacy, tolerability and safety of Sativex(®) (nabiximols) as an add-on therapy in alleviating bladder symptoms in patients with MS. METHODS: We un…

Read More

Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes.

By | Anorexia, Behavioral Health, Brain Disorders, Clinical Endocannabinoid Deficiency, Digestive System Diseases, Headache Disorders, Immune System Diseases , Irritable Bowel Syndrome, Multiple Sclerosis, Nervous System Diseases, Parkinsonian Disorders, Stress Disorders - Post-Traumatic

Authors: Ethan B. Russo
Cannabis and Cannabinoid Research, 1 July 2016

Medicine continues to struggle in its approaches to numerous common subjective pain syndromes that lack objective signs and remain treatment resistant. Foremost among these are migraine, fibromyalgia, and irritable bowel syndrome, disorders that may overlap in their affected p…

Read More

Cannabinoids and autoimmune diseases: A systematic review

By | Immune System Diseases 

Authors: Valeria Katchan, Paula David, Yehuda Shoenfeld
Autoimmunity Reviews, June 2016

Cannabinoids have shown to have a variety effects on body systems. Through CB1 and CB2 receptors, amongst other, they exert an effect by modulating neurotransmitter and cytokine release. Current research in the role of cannabinoids in the immune system shows that they possess…

Read More

Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study.

By | Immune System Diseases 

Authors: Moshe Yeshurun, Ofer Shpilberg, Corina Herscovici, Liat Shargian, Juliet Dreyer, et al
Biology of Blood and Marrow Transplantation, October 2015

Graft-versus-host-disease (GVHD) is a major obstacle to successful allogeneic hematopoietic cell transplantation (alloHCT). Cannabidiol (CBD), a nonpsychotropic ingredient of Cannabis sativa, possesses potent anti-inflammatory and immunosuppressive properties. We hypothesized…

Read More

Δ⁹-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells.

By | Immune System Diseases 

Authors: Jessica M. Sido, Prakash S. Nagarkatti, Mitzi Nagarkatti
Journal of Leukocyte Biology, September 2015

Immune cells have been shown to express cannabinoid receptors and to produce endogenous ligands. Moreover, activation of cannabinoid receptors on immune cells has been shown to trigger potent immunosuppression. Despite such studies, the role of cannabinoids in transplantation…

Read More

Medical Marijuana for Treatment of Chronic Pain and Other Medical and Psychiatric Problems: A Clinical Review.

By | Immune System Diseases , Medical Cannabis, Multiple Sclerosis, Muscle Spasticity, Muscular Diseases, Nervous System Diseases, Neuromuscular Diseases, Pain

Authors: Kevin P. Hill
JAMA, 23 June 2015

IMPORTANCE: As of March 2015, 23 states and the District of Columbia had medical marijuana laws in place. Physicians should know both the scientific rationale and the practical implications for medical marijuana laws. OBJECTIVE: To review the pharmacology, indications, and law…

Read More

Role of Endocannabinoid Activation of Peripheral CB1 Receptors in the Regulation of Autoimmune Disease.

By | Arthritis, Immune System Diseases , Joint Diseases (Arthrosis), Multiple Sclerosis

Authors: Jessica Margaret Sido, Prakash S. Nagarkatti, Mitzi Nagarkatti
International Reviews of Immunology, 2015

The impact of the endogenous cannabinoids (AEA, 2-AG, PEA, and virodamine) on the immune cell expressed cannabinoid receptors (CB1, CB2, TRPV-1, and GPR55) and consequent regulation of immune function is an exciting area of research with potential implications in the preventio…

Read More